Caris Life Sciences (CAI) Total Non-Current Liabilities (2024 - 2026)

Caris Life Sciences has reported Total Non-Current Liabilities for 3 years, with the latest figure at $584.4 million in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities rose 26.01% year-over-year to $584.4 million in Q2 2026; TTM through Jun 2026 was $584.4 million, a 26.01% increase from a year earlier, with the FY2025 full-year figure at $506.0 million, down 4.4% from the prior year.
• Total Non-Current Liabilities was $584.4 million for Q2 2026 at Caris Life Sciences, up from $525.3 million in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $584.4 million in Q2 2026, with the low at $462.3 million in Q3 2025.
• Average Total Non-Current Liabilities over 3 years is $511.8 million, with a median of $515.6 million recorded in 2025.
• The sharpest annual moves came in 2025 and 2026: Total Non-Current Liabilities dropped 4.4% in 2025, then rose 26.01% in 2026.
• Over 3 years, Total Non-Current Liabilities stood at $529.3 million in 2024, then fell by 4.4% to $506.0 million in 2025, then gained by 15.5% to $584.4 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $584.4 million (Q2 2026), $525.3 million (Q1 2026), and $506.0 million (Q4 2025), per Business Quant data.